Ultime notizie per Precipio (NASDAQ:PRPO) Azioni

Precipio

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Precipio Inc

William Blair analyst Matt Phipps initiates coverage on Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Outperform rating.

News

Initiation

Analyst Ratings

CNTX

William Blair Initiates Coverage On Context Therapeutics with Outperform Rating

William Blair analyst Matt Phipps initiates coverage on Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform rating.

XNCR

William Blair Initiates Coverage On Xencor with Outperform Rating

Wedbush analyst Seth Basham maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Outperform and maintains $90 price target.

Price Target

Wedbush Maintains Outperform on CarMax, Maintains $90 Price Target

Bernstein analysts on Monday identified five structural forces that could drive Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) trajectory in the coming months, based on rising institutional demand, regulatory developments and <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44499889/bitcoin-is-fulfilling-its-destiny-as-world-reserve-currency-says-bitcoin-whale-trace-mayer">new U.S. government initiatives</a>.
The findings, according to Bernstein, lay out key inflection points now anchoring Bitcoin&#8217;s position within global capital markets.
What Happened: According to the report, one of the core developments underpinning Bitcoin's market resilience is the establishment of a <a href="https://www.benzinga.com/news/25/04/44778849/peter-schiff-says-trumps-strategic-bitcoin-reserve-is-already-down-over-12-claims-if-wed-bought-gold-instead-wed-be-up-2-right-now">Strategic Bitcoin Reserve by the U.S. government</a>.
Originally funded through seized BTC assets held across federal agencies, the Bitcoin reserve move has been widely interpreted by analysts as formal recognition of Bitcoin as a sovereign-grade asset akin to digital gold.
This designation has already catalyzed renewed interest from corporate treasuries and sovereign entities.
A second catalyst highlighted is fresh institutional Bitcoin demand, particularly from corporate buyers and ETFs. 
Despite turbulence earlier this year, outflows from U.S.-listed Bitcoin ETFs have slowed, indicating a stickier base of long-term capital. 
Bernstein notes that around <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44898586/strategy-adds-555-million-in-bitcoin-ups-stash-to-538200-btc">80 corporates globally</a> now hold Bitcoin on their balance sheets.
The third driver comes from <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894658/deutsche-bank-standard-chartered-reportedly-looking-into-expanding-to-us-crypto-market">growing momentum in the banking sector</a>.
The report outlines that major banks, wealth managers and broker-dealers are ramping up efforts to integrate crypto into traditional financial services.
This includes custodial services, tokenized treasuries and the adoption of blockchain infrastructure for payments and settlement rails.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44896411/bitcoin-catapults-to-87000-what-is-going-on">Bitcoin Catapults To $87,000: What Is Going On?</a>
Bernstein's fourth key catalyst centers on the expected passage of the Stablecoin legislation in the U.S. this year. 
The bill is likely to <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44812762/stablecoins-to-surge-to-2-trillion-by-2028-says-standard-chartered-heres-what-it-means-for-the-dollar">institutionalize stablecoin operations</a> and embed them deeper into payment systems.
Stablecoins already settle over $1 trillion in monthly volume and are increasingly seen as tools for cross-border trade and B2B payments. 
The report calls this a foundational layer for the next generation of digital finance.
The final catalyst is a renewed push by asset managers and broker-dealers to embrace tokenization. 
Tokenized U.S. Treasuries already represent a $5 billion market, with BlackRock's BUIDL fund alone accounting for $2 billion. 
Bernstein points to this trend as validation of tokenized finance as a scalable infrastructure play rather than a speculative niche.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894658/deutsche-bank-standard-chartered-reportedly-looking-into-expanding-to-us-crypto-market">Deutsche Bank, Standard Chartered Reportedly Looking Into Expanding To US Crypto Market</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

5 Catalysts That Could Drive Bitcoin Higher: Bernstein

ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo
Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025
SEATTLE and VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that complete trial results from its ORCA-3 were published in the <a href="https://www.globenewswire.com/Tracker?data=AzbFrMUa4qC2IbEBD16NY2rJNGxPwdX0O0sSNUXm_aDNy28vyLWeW_-LrD35xDfNniKB7qenEIsDHhVOfNuzgqQBT5PhwPzigaGEAXCbGA0oMoKEGoLFcazCYGG_M0etUoLYv5WYKOzS0YzTCMvBN1yl8lF3OSfWZbTuyNSlDUCERj0Qbg1wwS-rkFa8zkSIjpcUbOhlVqybZdUOL5uKnKI0ps_T8Sz0eIlvT9YsuZs=">Journal of the American Medical Association (JAMA) Internal Medicine</a>. ORCA-3 was the second randomized, placebo-controlled Phase 3 clinical trial evaluating cytisinicline for smoking cessation in 792 U.S. adults. The authors concluded that ORCA-3 reaffirms cytisinicline's efficacy and tolerability for smoking cessation in adult smokers at both 6- and 12-week treatment durations, including reduction in nicotine cravings and extended cessation benefits through 24 weeks.
In addition to previously reported <a href="https://www.globenewswire.com/Tracker?data=xGGUKHvpcxeWCIC-Z8NndUDLz7kunUODptVNw36_g3bn81hVavT23ahXHl3YSWWPTZXXuEQI0szEHPNsvgJtsatTNmDU7dwGMmspJobqokCDGVER_nvCWRtOGqqzH87__skWCtumfg4fMfBW1vskjTo62km53Vx0rdLF9aXo9qoZq3un0dbhm20J-BoQWvvK-J3fmIaeO-r0ioXbCjP_qw==">topline results</a> announced in May 2023, the published completed trial results provided further evidence of cytisinicline's highly targeted effect on treating nicotine dependence by binding to specific nicotine receptors. These consistent results, now published from two large, randomized Phase 3 trials, demonstrated that cytisinicline significantly reduced nicotine cravings and increased the likelihood of quitting smoking. In clinical trials, cytisinicline was well tolerated, which is thought to be due to limited other off-target binding effects that can result in side effects known to be associated with currently available treatments.
Similar to the first Phase 3 trial, ORCA-3 participants had an average age of 53 years, smoked a median of 20 cigarettes per day at baseline, and had a median smoking history of 36 years with four prior quit attempts.

ACHV

Achieve Life Sciences Says Cytisinicline Phase 3 ORCA-3 Trial Results Showed Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo

Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) stock rallied over 20% on Monday following the <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">announcement of an acquisition</a>.
What Happened: The Israel-based company <a href="https://www.benzinga.com/pressreleases/25/04/n44893783/icl-to-acquire-the-activity-of-evogenes-subsidiary-lavie-bio" target="_blank" rel="noreferrer noopener">agreed</a> to sell a majority of Lavie Bio Ltd., its subsidiary, to ICL. 
Terms of the deal remain undisclosed.
ICL will also gain control of Evogene&#8217;s MicroBoost AI for AG platform.
This strategic acquisition strengthens ICL&#8217;s position in the ag-biologicals sector. Lavie Bio will continue its operations within ICL&#8217;s expanded structure. 
Key assets to be transferred to ICL include Lavie Bio&#8217;s core team, technology platform, microbial bank, and commercial products.
See Also: <a href="https://editorial.benzinga.com/wp-admin/post.php?post=879284&amp;action=edit">Gold Rallies To Record, Dollar Drops &#8211; Global Markets Today While US Slept</a>
Why It Matters: The transaction builds on more than two years of collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for agriculture.
&#8220;We believe this transaction unlocks significant value for Evogene&#8217;s shareholders,&#8221; said Ofer Haviv, CEO of Evogene. &#8220;Integrating Lavie Bio into ICL will accelerate progress in the global ag-biologicals market, driving innovation in agriculture.&#8221;
Price Action: EVGN shares are trading higher by 24.74% at $1.21 premarket Monday.
At last check, it was trading higher by almost 20.5%. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44896834/dollar-hits-3-year-lows-us-stocks-tumble-as-trump-threatens-to-fire-powell-contrarians-of-the-world-unite">Dollar Hits 3-Year Lows, US Stocks Tumble As Trump Threatens To Fire Powell: &#8216;Contrarians Of The World, Unite!&#8217;</a></li>
</ul>

BASFY

EVGN

THRY

Evogene Stock Soars After ICL Deal To Acquire Lavie Bio, MicroBoost AI

Snap-on&#xAE; announced today its diagnostic platforms have been&nbsp; approved by Mercedes-Benz USA and certified by Auto Authentication Authority (AutoAuth) to access&nbsp; Mercedes Benz vehicles' gateway modules. The ability to work with Mercedes-Benz secure systems is&nbsp; available on Snap-on Wi-Fi enabled products operating the latest software.&nbsp; Automobile manufacturers are developing solutions to protect their vehicles' networks from unauthorized&nbsp; access, including potential cyber-attacks, by securing vital systems behind gateways. Mercedes-Benz,&nbsp; along with several other manufacturers, have implemented a secure gateway module that was&nbsp; introduced on a selection of 2021 and newer model vehicles. For those vehicles with the secure gateway&nbsp; module, access to certain diagnostic functions requires registration and authentication through an&nbsp; approved device for all aftermarket scan tools

MERCEDES-BENZ UNSP / ADR by Mercedes Benz Group AG

MBGYY

Snap-on Approved For Access To Mercedes-Benz Secured Gateway Vehicles

Stifel analyst Brian Brophy maintains Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) with a Buy and lowers the price target from $16 to $15.

TTAM

Stifel Maintains Buy on Titan America, Lowers Price Target to $15

Stifel analyst Jonathan Block maintains Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) with a Buy and lowers the price target from $15 to $14.

NYXH

Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14

Stifel analyst Jonathan Block maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Hold and lowers the price target from $190 to $175.

INSP

Stifel Maintains Hold on Inspire Medical Systems, Lowers Price Target to $175

A few thematic and leveraged ETFs shone last week, posting solid gains as other markets retreated due to worries over geopolitics and macroeconomic uncertainty. Across the spectrum, from biotech and streaming to crypto and transportation, some funds flashed decent returns.
T-Rex 2X Long DJT Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DJTU#BATS">DJTU</a>) jumped 33.5%, the week&#8217;s best performer as the Dow Jones Transportation Average recovered on Thursday.
Defiance Daily Target 2X Long LLY ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLYX#NYSE">LLYX</a>) rose 22.3% as Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares soared 11.34%. Investors remain optimistic about the company&#8217;s blockbuster weight-loss and diabetes medications, which continue to drive revenue growth and provide robust forward guidance.
Direxion Daily NFLX Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFXL#NASDAQ">NFXL</a>) gained 8.8%, echoing the<a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering"> robust quarterly performance</a> of Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). The streaming behemoth surpassed Wall Street expectations, with the increase in its ad-supported plan and better content performance providing bulls a reason to rejoice.
SPDR Galaxy Digital Asset Ecosystem ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DECO#NASDAQ">DECO</a>) gained 5.5% as stabilizing Bitcoin prices and increasing institutional interest in digital asset infrastructure supported it. Favorable sentiment in the overall crypto market helped support the fund&#8217;s holdings in blockchain and crypto-exposed assets.
Yieldmax MSTR Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSTY#NYSE">MSTY</a>) increased by 3%, taking advantage of MicroStrategy&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) solid performance and consistent returns earned from its options-based income strategy based on Bitcoin.
These ETF profits were impressive compared to the broader market&#8217;s losses during the last holiday-shortened week.
What Happened In The Markets Last Week
Markets were rattled by fresh geopolitical tensions and hawkish central bank commentary. The largest drag was from the technology sector, following Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) announcement that it had been informed by the Trump administration that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44886016/nvidias-do-not-enter-sign-caught-in-a-category-5-tariff-storm">exports of its H20 AI chip to China </a>would need a license. The firm warned that the export controls would lower earnings by $5.5 billion, pushing its shares down 8.5%. The news also <a href="https://www.benzinga.com/25/04/44799456/chip-shock-3-hot-semiconductor-etfs-to-watch-as-trumps-tariff-bomb-ticks">affected the wider chip industry</a>, with the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) losing 3%—its seventh loss in the last eight weeks.
Earnings were mixed. While banks and Netflix reported positive results, UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) surprised markets by cutting its full-year forecast. The stock lost 22.4% in one session—the worst one-day decline for the insurer since 1998.
On the trade side, Canada temporarily paused counter measure tariffs on critical U.S. imports to relieve cross-border supply chain stress—most notably helping Midwest-based auto manufacturers.
Meanwhile, Federal Reserve Chairman Jerome Powell again expressed reluctance to cut interest rates, citing lingering inflation and risks to trade-driven growth. President Donald Trump condemned the move, calling Powell &#8220;always too late&#8221; and threatening to fire him before his term ends in May 2026. Trump spoke against a backdrop of irritation over the European Central Bank&#8217;s sixth consecutive interest rate reduction, further amplifying the divergence of monetary policies in developed nations.
Against this background of policy uncertainty and volatility, gold was the shining star. The SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) jumped to an all-time high of $3,330 per ounce, recording gains in 14 of the last 16 weeks, as investors flocked to the yellow metal for safety.
While headwinds beset the overall market, last week&#8217;s ETF action highlights where momentum—and investor confidence—is still present.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44876466/the-10k-handbag-hoax-tiktoks-trade-war-puts-luxury-etfs-in-the-hot-seat">The $10K Handbag Hoax? TikTok&#8217;s Trade War Puts Luxury ETFs In The Hot Seat</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

DECO

DJTU

LLYX

MSTR

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

MSTY

NFLX

NFXL

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

ETFs Last Week: Thematic ETFs Gleamed Against Market Gloom

Stifel analyst David Grossman maintains Infosys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) with a Hold and lowers the price target from $18 to $17.

INFY

Stifel Maintains Hold on Infosys, Lowers Price Target to $17

As of April 14, the Social Security Administration rolled out new anti-fraud policies aimed at protecting beneficiaries, but the changes have left many Americans confused, anxious, and scrambling to verify their identity in person. For those who rely on <a href="https://www.benzinga.com/25/04/44829975/joe-biden-calls-social-security-a-sacred-promise-slams-trump-administrations-efforts-to-damage-the-program-theyre-shooting-first-and-aiming-later">Social Security</a> as their primary source of income, the fear of missing even one payment is causing serious concern.
<h2 class="wp-block-heading">What's Changing With Social Security's Anti-Fraud Efforts?</h2>
The SSA now uses enhanced technology to detect suspicious activity in phone-based applications for benefits. If a claim raises red flags, the individual will need to verify their identity in person at a local field office. In addition, beneficiaries can no longer change their direct deposit information by phone — a move the agency says is necessary due to high levels of fraud tied to those calls.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
The SSA has stated that about 40% of direct deposit fraud cases come from people calling in to change their bank details. Going forward, any changes must be made online through the "my Social Security" portal or in person at an SSA office.
"We are modernizing how we serve the public — enhancing both security and accessibility," Acting Commissioner of Social Security Leland Dudek said in a <a href="https://www.ssa.gov/news/press/releases/2025/#2025-04-12">press release</a>.
<h2 class="wp-block-heading">Many Beneficiaries Are Alarmed — and Taking Action</h2>
Despite the SSA's intention to make the process safer, many Americans misunderstood the changes. Some believed they had to verify their identity in person regardless of whether they were flagged for fraud. This led to <a href="https://www.benzinga.com/personal-finance/25/02/44063062/thousands-face-longer-waits-as-social-security-offices-close-see-the-affected-locations">long lines at field offices</a> and overwhelmed phone lines.
Kevin Jochems, a 62-year-old cancer patient from Colorado, went to his local SSA office last month, fearing he might lose his only source of income if he didn't act. "Even missing one monthly benefit would put me on step to homelessness," Jochems told <a href="https://edition.cnn.com/2025/04/14/politics/social-security-changes-fraud/index.html">CNN</a>. He was turned away without help and later disconnected while calling the agency's main phone line.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Others, like 66-year-old Matt Koob in Florida, are worried about the impact these changes could have when they file for benefits in the near future. "They're telling people, ‘We will want you to do it in person, but we're not going to let you in the building,'" he told CNN.
<h2 class="wp-block-heading">Policy Reversals Added to the Confusion</h2>
Initially, the SSA announced it would stop taking phone applications for retirement and other benefits, requiring people to apply online or in person. That decision was met with <a href="https://www.benzinga.com/personal-finance/25/04/44585316/social-security-administration-relaxes-id-verification-rules-after-backlash-from-lawmakers-and-a">backlash from advocates</a> who said it would disproportionately affect older Americans who aren't tech-savvy or who have mobility issues.
After public concern and internal pushback, the SSA reversed course twice. Now, applications by phone remain available for all programs. Only those flagged for potential fraud must appear in person.
"Telephone remains a viable option to the public," the agency said <a href="https://x.com/SocialSecurity/status/1909710597324964065">on X</a>.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Advocates Call the Revisions a Win for Seniors</h2>
Groups like AARP applauded the updated guidance. "SSA's guarantee of phone access for claims is a win for older Americans," <a href="https://www.aarp.org/social-security/planned-id-verification-requirements-eased.html">said</a> Nancy LeaMond, executive vice president at AARP.
But even with the reversals, not all SSA employees were brought up to speed in time. Union officials told CNN that SSA staff received new training videos just days before the rollout and had only hours to review them, leaving many unsure how to help confused beneficiaries.
<h2 class="wp-block-heading">Bottom Line</h2>
While the <a href="https://www.benzinga.com/25/03/44476777/ssa-announces-service-upgrades-and-new-identity-verification-measures-what-it-means-for-you">SSA's anti-fraud measures</a> are designed to protect the integrity of the system, the rollout has revealed gaps in communication and support. For Americans living paycheck to paycheck, the fear of losing even one Social Security payment is real — and the agency's challenge now is to balance fraud prevention with accessibility and clarity.
Read Next:
<ul>
<li>With high-demand properties in the Midwest, Bam Capital has delivered 2.46x equity multiples in just over 3 years. No losses. No missed payments. <a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">Learn more about becoming an investor today</a>. </li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Even Missing One Monthly Benefit Would Put Me On Step To Homelessness': Americans React to Social Security's New Anti-Fraud Rules

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 10 years by 1.54% on an annualized basis producing an average annual return of 10.84%. Currently, AECOM has a market capitalization of $12.35 billion. 
Buying $100 In ACM: If an investor had bought $100 of ACM stock 10 years ago, it would be worth $278.04 today based on a price of $93.10 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745248511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In AECOM 10 Years Ago Would Be Worth Today

Stifel analyst Nathan Jones maintains Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) with a Hold and raises the price target from $196 to $200.

Stifel Maintains Hold on Badger Meter, Raises Price Target to $200

BMO Capital analyst James Thalacker maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Outperform and raises the price target from $111 to $115.

BMO Capital Maintains Outperform on American Electric Power, Raises Price Target to $115

Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) with a Outperform and maintains $43 price target.

EWTX

Wedbush Maintains Outperform on Edgewise Therapeutics, Maintains $43 Price Target

Barclays analyst Andrew Mok maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $642 to $560.

Barclays Maintains Overweight on UnitedHealth Group, Lowers Price Target to $560

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower amid President Trump's criticism of Fed Chair Powell. Weakness in NVIDIA may also be weighing on the Nasdaq while continued weakness in UnitedHealth weighs on the Dow.

BMO Capital analyst James Thalacker maintains DTE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) with a Market Perform and raises the price target from $135 to $142.

Comments

Precipio

Notizie

Ultime notizie per Precipio (NASDAQ:PRPO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO